Navigation Links
Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants

WORCESTER, Mass., Nov. 10, 2010 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTC Bulletin Board: GNBT) announced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (, has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

The Antigen Express Therapeutic Discovery Projects are entitled:

  • Ii-Key Her-2/neu Peptide Vaccine, for the treatment of breast cancer
  • Ii-Key Her-2/neu Peptide Vaccine, for the treatment of prostate cancer

The proprietary vaccine being developed by Antigen Express is an off-the-shelf product designed to reduce the risk of relapse in cancer patients.  It is the subject of a controlled, randomized Phase II trial in patients with breast cancer which has yielded positive interim results.  Based on positive results from a Phase I trial in prostate cancer patients, preparations for a Phase II clinical trial in prostate cancer patients are underway.  In all studies, the self-potentiating vaccine has shown very low toxicity and generates a good immune response.  

The Therapeutic Discovery Project grants are targeted for projects that show a reasonable potential to: result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions; reduce the long-term growth of health care costs in the United States; or, significantly advance the goal of curing cancer within 30 years.  Grant allocations also take into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs, and to advance U.S. competitiveness in life, biological, and medical sciences. 

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at or the Antigen Express website at

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
2. Generex to Participate in Canadian Diabetes Association Conference
3. Generex Reschedules Live Video Webcast
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
6. Generex Provides Clarification for Special Meeting Voting
7. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
10. Generex Presents Abstract at EASD Annual Meeting
11. Generex Announces Sales Agreement with Elias Shaker & Company
Post Your Comments:
(Date:10/13/2015)... DIEGO , October 13, 2015 ... today announced the appointment of Harry Lander , PhD ... the Company,s Chairman & CEO David Koos as ... small molecule and immuno-oncological therapeutics. --> Regen ... the appointment of Harry Lander , PhD as its ...
(Date:10/13/2015)...  Yesterday Congresswoman Renee Ellmers (R-NC-02) visited ... located in Holly Springs, NC . ... ® (Influenza Vaccine) using cell-culture technology, a state-of-the-art production ... is not reliant on chicken eggs. 1,2 On ... business of Novartis AG in the US, which for ...
(Date:10/12/2015)... 12, 2015 Given the intricacy of ... challenging to deliver an ophthalmic drug effectively to a specific ... successful ocular drug delivery. These include dilution of a drug ... of conjunctiva and drug permeation issues with respect to the ... topical eye drops, is lost due to the aforementioned barriers. ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... companies in the United States, today announced the release of its limited edition ... new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and delicious ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits ... GPUG Summit and NAVUG Summit are independent user conferences designed and led by ...
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist ... on September 18, 2015. The research, which was conducted at the Dental Institute at ... colleagues, show connections between stress during pregnancy and future dental health in the child. ...
(Date:10/13/2015)... ... ... Protein is essential to good health. You need it to make the bricks ... does the average man need in order to stay healthy? , The answer ... Harvard Men's Health Watch . Most Americans get about 15% of their calories ...
(Date:10/13/2015)... ... October 13, 2015 , ... Georgia Partnership ... in communities throughout Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) ... telehealth summits for Fall 2015. , Each of the three conferences share ...
Breaking Medicine News(10 mins):